MoonLake Immunotherapeutics
MLTX
$3.28
Change (1 day)
$64.98
Year High
$35.11
Year Low
Categories
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
P/E ratio for MoonLake Immunotherapeutics (MLTX)
P/E ratio as of 2023: -82.39
According to MoonLake Immunotherapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -82.39. At the end of 2022 the company had a P/E ratio of -4.78.
P/E ratio history for MoonLake Immunotherapeutics from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -82.39 |
| 2022 | -4.78 |
| 2021 | -1.45 |
| 2020 | -1853.11 |